Loading
Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Relacorilant with nab-paclitaxel is a new option for platinum-resistant disease that does not depend on folate receptor status, with regulatory review following the trial.
Folate receptor alpha testing is now standard in platinum-resistant ovarian cancer and mirvetuximab is the preferred treatment for high-expressing tumours, with an eye-care protocol.
Bevacizumab with weekly paclitaxel or other single agents is a standard for platinum-resistant ovarian cancer in bevacizumab-naive patients, and the control regimen for later trials such as MIRASOL and ROSELLA.
Bevacizumab with weekly paclitaxel, liposomal doxorubicin or topotecan is a standard option in platinum-resistant ovarian cancer; approved in the United States in 2014.
Query for this cancer: (TITLE:"Platinum-resistant ovarian cancer" OR ABSTRACT:"Platinum-resistant ovarian cancer" OR TITLE:"Platinum-resistant recurrent ovarian cancer" OR ABSTRACT:"Platinum-resistant recurrent ovarian cancer" OR TITLE:"Platinum-refractory ovarian cancer" OR ABSTRACT:"Platinum-refractory ovarian cancer" OR TITLE:"Platinum-free interval under six months" OR ABSTRACT:"Platinum-free interval under six months" OR TITLE:"PROC" OR ABSTRACT:"PROC") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Platinum-resistant ovarian cancer, not a curated reading list.